MedeliX
Start asking

Cabergoline

Cabaseril, Dostinex · ATC code G02CB03

Also known as: Cabergolin, Kabergolin · Brand names: Cabaseril, Dostinex, Cabergoletten, Cabergolin Puren, Cabergolin Ratiopharm, Cabergoline Ratiopharm, Cabergoline Teva

Key facts
Active substance
Cabergoline
Drug class
Prolactine inhibitors
ATC code
G02CB03
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Cabergoline is an ergot-derived dopamine agonist. Per the US prescribing information, it is used to treat hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

What it is used for

  • Hyperprolactinemic disorders, idiopathic or due to pituitary adenomas
  • Not indicated for the inhibition or suppression of physiologic postpartum lactation

Dosing

  • Initially 0.25 mg twice a week
  • May be increased by 0.25 mg twice weekly up to 1 mg twice a week according to the serum prolactin level, no more rapidly than every 4 weeks
  • Before starting, a cardiovascular evaluation should be performed and echocardiography considered; on long-term treatment, cardiac status should be assessed periodically
  • After a normal prolactin level has been maintained for 6 months, cabergoline may be discontinued with periodic prolactin monitoring
  • Hepatic impairment: caution and careful monitoring; elderly patients: usually start at the low end of the dosing range

Contraindications

  • Uncontrolled hypertension
  • Known hypersensitivity to ergot derivatives
  • History of cardiac valvular disorders (valvulopathy of any valve)
  • History of pulmonary, pericardial or retroperitoneal fibrotic disorders

Important warnings

  • Cardiac valvulopathy: all patients should have a cardiovascular evaluation including echocardiogram; do not treat if valvular disease is found
  • Other fibrotic complications (pulmonary, pericardial, retroperitoneal)
  • Pregnancy-induced hypertension (e.g. preeclampsia, eclampsia, postpartum hypertension): dopamine agonists should generally not be used unless the benefit outweighs the risk
  • Orthostatic hypotension; caution with other blood-pressure-lowering medications
  • Impulse control/compulsive behaviors such as pathological gambling, increased libido and hypersexuality

Side effects

  • Most common in a placebo-controlled study: nausea (27%), headache (26%), dizziness (15%), constipation (10%), asthenia (9%) and fatigue (7%)
  • Also: abdominal pain, somnolence, postural hypotension, depression
  • Serious: cardiac valvulopathy and fibrotic disorders

Interactions

  • Should not be given with D2 antagonists such as phenothiazines, butyrophenones, thioxanthenes or metoclopramide
  • Caution with other drugs that lower blood pressure

Pregnancy and breastfeeding

  • No adequate and well-controlled studies in pregnant women; should be used during pregnancy only if clearly needed
  • Interferes with lactation; should not be given to postpartum women who are breastfeeding or planning to breastfeed

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • CabaserilPfizer Corporation Austria Ges.M.B.H. · 1 register entry
  • DostinexPfizer Corporation Austria Ges.M.B.H. · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • CabaserilPfizer Pharma Gmbh · 1 register entry
  • CabergolettenRenata Pharmaceuticals (Ireland) Limited · 1 register entry
  • Cabergolin PurenPuren Pharma Gmbh & Co. Kg · 1 register entry
  • Cabergolin RatiopharmRatiopharm Gmbh · 1 register entry
  • Cabergoline RatiopharmRatiopharm Gmbh · 1 register entry
  • Cabergoline TevaTeva Gmbh · 1 register entry
  • DostinexPfizer Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • DostinexPFİZER PFE İLAÇLARI A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 23 more European countries
Belgium
Cabergoline Teva, Dostinex, Sostilar
Bulgaria
Достинекс
Croatia
Dostinex
Cyprus
Dostinex
Czechia
Dostinex
Denmark
Cabenex, Cabergolin Teva, Dostinex
Finland
Cabaser, Dostinex
France
Cabergoline Arrow, Cabergoline Biogaran, Cabergoline Teva, Cabergoline Zentiva, Dostinex
Greece
Dostinex
Iceland
Dostinex
Ireland
Cabaser, Cabergoline Renata Pharmaceuticals (Ireland), Dostinex
Italy
Cabaser, Cabergolina Aurobindo, Cabergolina Doc, Cabergolina Ratiopharm, Cabergolina Renata, Cabergoline Ratiopharm, Dostinex
Latvia
Dostinex
Luxembourg
Cabergoline Teva, Dostinex, Sostilar
Malta
Cabergoline Aurobindo, Cabergoline Doc, Dostinex
Netherlands
Cabergoline Aurobindo, Cabergoline Pch, Cabergoline Renata, Dostinex
Norway
Cabergoline Renata Pharmaceuticals (Ireland), Dostinex
Poland
Dostinex
Portugal
Cabergolina Generis, Cabergoline, Dostinex
Romania
Dostinex
Slovakia
Cabest
Spain
Cabergolina Teva, Dostinex, Sogilen
Sweden
Cabenex, Cabergoline Ratiopharm, Cabergoline Teva, Dostinex

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Cabergoline (SOLA Pharmaceuticals, LLC) – Prescribing Information, 2025-12-08. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=275a6a25-c3c9-4258-a610-0b00752517f7
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC G02CB.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.